Candel Therapeutics (CADL) Leases (2022 - 2025)

Candel Therapeutics has disclosed Leases across 4 years of filings, most recently posting $1.7 million for Q4 2025.

• Leases for Q4 2025 came in at $1.7 million, up 206.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 million (up 206.46% YoY), and the FY2025 annual result was $1.7 million, up 206.46% from the prior year.
• Leases came in at $1.7 million for Q4 2025 at Candel Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Leases ranged from a high of $1.8 million in Q3 2025 to a low of $391000.0 in Q2 2025.
• The 4-year median for Leases is $909500.0 (2023), against an average of $940000.0.
• Peak annual rise in Leases reached 206.46% in 2025, while the deepest fall reached 42.84% in 2025.
• Candel Therapeutics' Leases stood at $1.1 million in 2022, then retreated by 22.73% to $816000.0 in 2023, then plunged by 33.58% to $542000.0 in 2024, then soared by 206.46% to $1.7 million in 2025.
• The last three Leases figures came in at $1.7 million (Q4 2025), $1.8 million (Q3 2025), and $391000.0 (Q2 2025), per Business Quant data.